Response to Comments: MolDX: EndoPredict Breast Cancer Gene Expression Test

This excerpt is an administrative response-to-comments notice for the MolDX: EndoPredict Breast Cancer Gene Expression Test and contains only procedural dates (comment period 06/21/2017–08/06/2017; notice period 01/18/2018–03/05/2018) and the LCD effective date of 03/06/2018. No clinical coverage criteria, indications, limitations, documentation requirements for claims, or frequency limits are present in the provided text. Consult the full LCD/A55876 document for the detailed coverage rules and claim documentation requirements.